Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17139287 | COMPUTATIONAL REDUCTION VACCINE FOR COVID-19 BIN75 | December 2020 | February 2023 | Allow | 25 | 2 | 0 | Yes | No |
| 17119308 | METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV VECTORS | December 2020 | March 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17110876 | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES | December 2020 | November 2022 | Allow | 24 | 0 | 0 | No | No |
| 15734586 | NOVEL STREPTOCOCCUS SUIS BACTERIOPHAGE STR-SUP-1 AND USE THEREOF IN INHIBITING STREPTOCOCCUS SUIS BACTERIUM PROLIFERATION | December 2020 | February 2024 | Abandon | 39 | 1 | 0 | No | No |
| 15734589 | NOVEL STREPTOCOCCUS SUIS BACTERIOPHAGE STR-SUP-3, AND USE THEREOF FOR INHIBITING PROLIFERATION OF STREPTOCOCCUS SUIS STRAINS | December 2020 | February 2024 | Abandon | 39 | 1 | 0 | No | No |
| 15734587 | NOVEL STREPTOCOCCUS SUIS BACTERIOPHAGE STR-SUP-2, AND USE THEREOF FOR INHIBITING PROLIFERATION OF STREPTOCOCCUS SUIS STRAINS | December 2020 | February 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17058113 | IMMUNE CHECKPOINT INHIBITOR CO-EXPRESSION VECTORS | November 2020 | January 2024 | Abandon | 38 | 1 | 1 | No | No |
| 16951004 | RATIONAL POLYPLOID ADENO-ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF DISEASE | November 2020 | February 2023 | Allow | 27 | 0 | 1 | No | No |
| 17096076 | METHOD AND APPARATUS FOR DETECTING VIRUSES IN BIOLOGICAL SAMPLES | November 2020 | December 2022 | Abandon | 25 | 1 | 0 | No | No |
| 17092941 | SIV AND HIV VACCINATION USING RHCMV- AND HCMV-BASED VACCINE VECTORS | November 2020 | April 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17089468 | METHODS OF PRODUCING CELLS RESISTANT TO HIV INFECTION | November 2020 | May 2024 | Allow | 42 | 2 | 0 | No | Yes |
| 17250020 | MULTIEPITOPE FUSION ANTIGENS FOR VACCINATION AND METHODS OF MAKING AND USING SUCH ANTIGENS | November 2020 | July 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17063022 | ANTIGEN PURIFICATION | October 2020 | February 2023 | Allow | 29 | 2 | 0 | No | No |
| 17037826 | METHOD FOR PREPARING FOOT-AND-MOUTH DISEASE VIRUS-LIKE PARTICLES, AND TEST STRIP FOR DETECTING FOOT-AND-MOUTH DISEASE | September 2020 | August 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17037966 | ADENOVIRAL VECTORS COMPRISING PARTIAL DELETIONS OF E3 | September 2020 | March 2023 | Allow | 29 | 1 | 1 | No | No |
| 17024392 | BINDING AGENTS TO PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN | September 2020 | June 2022 | Allow | 21 | 1 | 1 | No | No |
| 17018693 | Methods and Systems for the Rapid Detection of Bacteria Using Recombinant Bacteriophage to Express an Indicator Subunit | September 2020 | September 2022 | Allow | 24 | 0 | 1 | No | No |
| 16977648 | COMPOSITIONS AND METHODS FOR REDUCING SERUM TRIGLYCERIDES | September 2020 | December 2022 | Allow | 27 | 1 | 1 | No | No |
| 16977408 | COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES | September 2020 | October 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16977290 | INDUCTION AND ENHANCEMENT OF ANTITUMOR IMMUNITY INVOLVING SINDBIS VIRUS VECTORS EXPRESSING IMMUNE CHECKPOINT PROTEINS | September 2020 | June 2024 | Allow | 45 | 1 | 1 | No | No |
| 17008126 | Method of Treatment for HIV Infection | August 2020 | May 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17001774 | Producing Recombinant SARS-CoV-2 Spike Protein in a Pre-fusion State | August 2020 | April 2021 | Allow | 8 | 2 | 1 | No | No |
| 16968397 | IMPROVED ADENO-ASSOCIATED VIRUS VECTOR | August 2020 | October 2023 | Allow | 38 | 2 | 1 | No | No |
| 16941780 | RETROVIRAL TRANSDUCTION USING POLOXAMERS | July 2020 | September 2022 | Allow | 26 | 1 | 1 | No | No |
| 16925438 | IMMUNOGENIC COMPOSITION FORMING A SARS-CoV-2 VACCINE, AND A METHOD FOR ITS MANUFACTURE | July 2020 | November 2021 | Allow | 16 | 1 | 1 | Yes | No |
| 16959632 | MODIFIED ORTHOPOXVIRUS VECTORS | July 2020 | June 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16909323 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES COMPRISING REDUCED-AFFINITY IMMUNOMODULATORY POLYPEPTIDES | June 2020 | November 2022 | Allow | 29 | 1 | 1 | No | No |
| 16905656 | BACTERIAL DELIVERY VEHICLES COMPRISING TRACER NUCLEIC ACID SEQUENCES | June 2020 | April 2022 | Allow | 22 | 3 | 1 | No | No |
| 16900704 | METHODS AND MATERIALS FOR DETECTING SNPS AND ADMINISTERING MEASLES VIRUS | June 2020 | September 2021 | Allow | 15 | 0 | 0 | No | No |
| 16897734 | COMBINATION HMPV/RSV RNA VACCINES | June 2020 | August 2023 | Allow | 38 | 4 | 1 | No | No |
| 16770192 | BIOLUMINESCENT SCREENING TEST FOR DETECTING CELL CYTOLYSIS | June 2020 | April 2024 | Abandon | 46 | 3 | 0 | No | No |
| 16880829 | BETACORONAVIRUS MRNA VACCINE | May 2020 | September 2020 | Allow | 4 | 1 | 0 | No | No |
| 16877015 | NOROVIRUS VACCINE | May 2020 | November 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16865652 | GLYCOSIDASE REGIMEN FOR TREATMENT OF INFECTIOUS DISEASE | May 2020 | December 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16759652 | TYMOVIRUS VIRUS AND VIRUS-LIKE PARTICLES AS NANOCARRIERS FOR IMAGING AND THERAPEUTIC AGENTS | April 2020 | March 2023 | Allow | 35 | 2 | 0 | No | No |
| 16759222 | CAR T-CELLS COMPRISING TRANSCRIPTIONAL CIRCUITS | April 2020 | August 2023 | Allow | 39 | 2 | 1 | No | No |
| 16758364 | MEASUREMENT OF AFUCOSULATED IgG Fc GLYCANS AND RELATED VACCINATION METHODS | April 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16757707 | SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES | April 2020 | December 2022 | Allow | 32 | 0 | 1 | No | No |
| 16756573 | MARKERS OF ACTIVE HIV RESERVOIR | April 2020 | May 2023 | Allow | 37 | 2 | 1 | No | No |
| 16756632 | COMPOSITION AND METHOD FOR ACTIVATING LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV) | April 2020 | November 2022 | Allow | 31 | 1 | 1 | No | No |
| 16756373 | ENHANCED PROMOTER | April 2020 | February 2022 | Allow | 22 | 1 | 0 | No | No |
| 16846250 | VIRAL FUSION PROTEIN TREATMENT FOR CCR8 MEDIATED DISEASES | April 2020 | December 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16755033 | LENTIVIRAL VECTORS FOR DELIVERY OF PKLR TO TREAT PYRUVATE KINASE DEFICIENCY | April 2020 | December 2022 | Allow | 32 | 1 | 0 | No | No |
| 16834359 | GENETICALLY STABLE RECOMBINANT MODIFIED VACCINIA ANKARA (RMVA) VACCINES AND METHODS OF PREPARATION THEREOF | March 2020 | August 2022 | Allow | 29 | 3 | 0 | No | No |
| 16826985 | METHODS OF MAKING ANTI-GP41 ANTIBODY-SPECIFIC CAPTURE AGENTS | March 2020 | March 2022 | Allow | 24 | 1 | 1 | No | No |
| 16649164 | SOD1 DUAL EXPRESSION VECTORS AND USES THEREOF | March 2020 | March 2023 | Allow | 36 | 1 | 1 | No | No |
| 16643282 | MEDICATION FOR INFLUENZA | February 2020 | July 2024 | Abandon | 52 | 3 | 1 | No | No |
| 16805587 | BETACORONAVIRUS MRNA VACCINE | February 2020 | May 2020 | Allow | 2 | 0 | 1 | No | No |
| 16805686 | DIRECT VISUALIZATION OF INTEGRATED STRESS RESPONSE ACTIVITY | February 2020 | October 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16642690 | VACCINE AND THERAPEUTIC COMPOSITIONS COMPRISING ANTIGEN-CONJUGATED VIRAL CAPSIDS | February 2020 | August 2022 | Allow | 29 | 2 | 1 | Yes | No |
| 16802089 | REDUCED FOAMING VACCINE COMPOSITIONS | February 2020 | April 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16786267 | NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE | February 2020 | July 2022 | Abandon | 30 | 2 | 1 | No | No |
| 16742150 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE CELLS | January 2020 | February 2022 | Allow | 25 | 1 | 1 | No | No |
| 16629521 | METHOD OF TESTING A GENE THERAPY VECTOR | January 2020 | July 2023 | Allow | 42 | 4 | 0 | No | No |
| 16726981 | ANTIBODY CAPABLE OF BINDING TO INFLUENZA VIRUS INTRANUCLEAR PROTEIN, COMPLEX, DETECTION APPARATUS AND DETECTION METHOD USING SAME | December 2019 | August 2021 | Allow | 20 | 2 | 1 | No | No |
| 16710131 | RECOMBINANT SIMIAN ADENOVIRAL VECTORS ENCODING A HETEROLOGOUS FIBER PROTEIN AND USES THEREOF | December 2019 | September 2021 | Allow | 22 | 1 | 0 | No | No |
| 16685516 | ONCOLYTIC T7 BACTERIOPHAGE HAVING CYTOKINE GENE AND DISPLAYING HOMING PEPTIDE ON CAPSID AND ITS USE FOR TREATING MELANOMA | November 2019 | March 2022 | Allow | 28 | 1 | 1 | No | No |
| 16681494 | BETARETROVIRUS EPITOPES AND RELATED METHODS OF USE | November 2019 | December 2022 | Allow | 37 | 2 | 1 | Yes | No |
| 16611627 | VIRUS-LIKE PARTICLES INCLUDING HBS-L ANTIGEN PROTEIN FOR CAUSING IMMUNE RESPONSE AGAINST HBV | November 2019 | August 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16611054 | COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | November 2019 | November 2022 | Allow | 36 | 1 | 1 | Yes | No |
| 16610472 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | November 2019 | November 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16664037 | MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION | October 2019 | August 2020 | Allow | 9 | 1 | 0 | No | No |
| 16663651 | NON-IMMUNOGENIC PROTEIN NANOPARTICLES WITH CANCER TARGETING ACTIVITY USING ALBUMIN-BINDING PEPTIDE | October 2019 | July 2024 | Allow | 56 | 4 | 1 | No | No |
| 16664039 | MAST CELL STABILIZERS FOR TREATMENT OF FEVER | October 2019 | April 2021 | Allow | 18 | 1 | 0 | No | No |
| 16607710 | SELECTABLE STEM CELL MODIFICATION FOR GENE THERAPY USING TRANSIENT CELL SURFACE MARKING OF MODIFIED CELLS USING MODIFIED CD4 MOLECULE | October 2019 | September 2023 | Abandon | 47 | 2 | 1 | No | No |
| 16606993 | TARGETED NEOEPITOPE VECTORS AND METHODS THEREFOR | October 2019 | June 2023 | Allow | 44 | 3 | 1 | Yes | No |
| 16606754 | MEMBRANE LIPID COATED VIRAL NANOPARTICLES AND METHOD OF USE | October 2019 | April 2022 | Allow | 30 | 2 | 1 | No | No |
| 16657366 | COMPOSITIONS AND METHODS FOR MANUFACTURING BACTERIOPHAGE CANCER VACCINES AND USES THEREOF | October 2019 | June 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16655516 | METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION | October 2019 | July 2021 | Allow | 21 | 2 | 0 | No | No |
| 16653188 | STABLE FORMULATIONS FOR THE ORAL ADMINISTRATION OF AMPHOTERICIN B AND RELATED METHODS | October 2019 | July 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16605066 | METHODS OF TREATING BLADDER CANCER WITH AN ONCOLYTIC VIRUS | October 2019 | March 2022 | Allow | 29 | 1 | 0 | No | No |
| 16598516 | THERAPEUTIC VACCINE FOR THE TREATMENT OF PAPILLOMAVIRUS LESIONS | October 2019 | June 2021 | Allow | 20 | 4 | 0 | No | No |
| 16598779 | RATIONAL POLYPLOID ADENO-ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF DISEASE | October 2019 | August 2020 | Allow | 10 | 1 | 0 | No | No |
| 16596474 | TRISPECIFIC ANTI-CD38, ANTI-CD28, AND ANTI-CD3 BINDING PROTEINS AND METHODS OF USE FOR TREATING VIRAL INFECTION | October 2019 | May 2022 | Allow | 31 | 1 | 1 | No | No |
| 16595595 | Methods of Detecting Influenza | October 2019 | December 2021 | Allow | 27 | 1 | 1 | No | No |
| 16585391 | METHOD AND SYSTEM FOR DETECTION OF MYCOBACTERIA IN HUMAN SAMPLES | September 2019 | January 2024 | Allow | 52 | 4 | 1 | No | No |
| 16498690 | DIAPHRAGM-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | September 2019 | October 2023 | Allow | 49 | 3 | 1 | No | No |
| 16497229 | COMPOSITIONS, METHODS AND KITS TO DETECT ADENOVIRUS NUCLEIC ACID | September 2019 | March 2022 | Allow | 29 | 2 | 1 | No | No |
| 16577175 | SOLUBLE AND IMMUNOREACTIVE VARIANTS OF HTLV CAPSID ANTIGEN P24 | September 2019 | October 2022 | Allow | 37 | 3 | 1 | Yes | No |
| 16575106 | MODIFIED PEDV SPIKE PROTEIN | September 2019 | June 2022 | Allow | 32 | 1 | 1 | No | No |
| 16494196 | COMPOSITIONS AND METHODS FOR TREATING PHENYLKETONURIA | September 2019 | July 2023 | Allow | 46 | 1 | 1 | No | No |
| 16562578 | FOAMY VIRAL VECTOR COMPOSITIONS AND METHODS FOR THE MANUFACTURE OF SAME | September 2019 | July 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16491176 | ANTI-BACTERIAL COMPOSITIONS AND USES THEREOF | September 2019 | February 2023 | Allow | 41 | 1 | 0 | No | No |
| 16490919 | ENGINEERED CELLS WITH DECREASED GENE EXPRESSION RESULTING IN INCREASED VIRAL PRODUCTION | September 2019 | January 2023 | Allow | 40 | 4 | 1 | No | No |
| 16552955 | COMPOSITION OR MATRIX FOR STORAGE OF BACTERIOPHAGES COMPRISING NANOFIBRILLAR CELLULOSE | August 2019 | September 2022 | Allow | 36 | 4 | 1 | Yes | No |
| 16544838 | METHODS FOR DETERMINING RESISTANCE OR SUSCEPTIBILITY TO HIV ENTRY INHIBITORS | August 2019 | May 2022 | Allow | 33 | 2 | 1 | No | No |
| 16530359 | ADENOVIRAL VECTORS COMPRISING PARTIAL DELETIONS OF E3 | August 2019 | July 2020 | Allow | 11 | 2 | 0 | No | No |
| 16482500 | NUCLEIC ACID VACCINE COMPOSITION COMPRISING A LIPID FORMULATION, AND METHOD OF INCREASING THE POTENCY OF NUCLEIC ACID VACCINES | July 2019 | September 2023 | Abandon | 49 | 5 | 1 | No | No |
| 16479663 | SOLUTION-BASED PLASMONIC SPECIFIC-BINDING PARTNER ASSAYS USING METALLIC NANOSTRUCTURES | July 2019 | January 2024 | Allow | 54 | 3 | 1 | No | No |
| 16477258 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN IMMUNE RESPONSE AGAINST ZIKA VIRUS | July 2019 | September 2021 | Allow | 26 | 1 | 1 | No | No |
| 16474661 | RETRO- AND LENTI-HBV HYBRID VECTORS AND CONSTRUCTS | June 2019 | May 2020 | Allow | 11 | 1 | 0 | No | No |
| 16445481 | METHOD FOR TREATING EPSTEIN-BARR VIRUS - POSITIVE CANCER WITH IMMUNOTHERAPY | June 2019 | November 2021 | Abandon | 29 | 2 | 0 | No | No |
| 16444576 | PHARMACEUTICAL COMPOSITIONS COMPRISING BACTERIAL DELIVERY VEHICLES AND USES THEREOF | June 2019 | May 2021 | Allow | 23 | 4 | 0 | Yes | No |
| 16437770 | VIRUS PURIFICATION | June 2019 | May 2020 | Allow | 11 | 1 | 0 | Yes | No |
| 16464645 | BACTERIOPHAGE-BASED ELECTROCHEMICAL BACTERIAL SENSORS, SYSTEMS, AND METHODS | May 2019 | February 2023 | Allow | 44 | 2 | 1 | No | No |
| 16402441 | Hemagglutinin-Binding Peptide | May 2019 | January 2020 | Allow | 8 | 0 | 1 | No | No |
| 16346178 | PHAGE-BASED DETECTION OF BORRELIOSIS AND MEANS THEREFOR | April 2019 | March 2023 | Allow | 47 | 4 | 1 | Yes | No |
| 16396676 | HIV VACCINATION COMPOSITIONS | April 2019 | January 2022 | Abandon | 33 | 2 | 1 | No | No |
| 16388681 | EPITOPE MAPPING METHOD | April 2019 | August 2021 | Allow | 28 | 1 | 1 | Yes | No |
| 16385455 | POLYCLONAL ANTIBODIES PRODUCED USING HIV-1 TRIMERIC ENVELOPE GLYCOPROTEIN SUBUNITS | April 2019 | November 2021 | Allow | 31 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KINSEY WHITE, NICOLE ERIN.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KINSEY WHITE, NICOLE ERIN works in Art Unit 1648 and has examined 764 patent applications in our dataset. With an allowance rate of 48.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner KINSEY WHITE, NICOLE ERIN's allowance rate of 48.4% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KINSEY WHITE, NICOLE ERIN receive 2.21 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KINSEY WHITE, NICOLE ERIN is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.3% benefit to allowance rate for applications examined by KINSEY WHITE, NICOLE ERIN. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 16.1% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 40.5% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 73.5% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.9% of allowed cases (in the 79% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.